Harvard Bioscience Inc. has announced a regulatory issue concerning its compliance with Nasdaq Listing Rule 5605(c)(2)$(A)$, which mandates a specific composition for its audit committee. The company currently has only two members on its Audit Committee due to the resignation of Alan Edrick, effective June 10, 2025. This falls short of the requirement, prompting Harvard Bioscience to notify the Nasdaq Stock Market LLC. The company plans to resolve this issue by appointing a new independent Board member as soon as possible. Meanwhile, it will utilize a cure period provided by Nasdaq, which allows until the next annual stockholder meeting or June 10, 2026, whichever comes first, to comply with the audit committee requirements.